In a comparison of vaccine vectors, Lm-LLO-PSA was also found to be the most effective at reducing prostate tumor burden in mice as compared to DNA and vaccinia virus-based vaccines expressing the same antigen. This evidence concerns the gene KLK3 and prostate neoplasm.